ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,187.67
0.00%
Dow Jones
39,056.39
0.44%
US Dollar vs MXN
16.9251
0.04%
Brent Oil
83.635
0.09%
Bitcoin
61,451.11
0.43%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Omega Therapeutics Inc (OMGA)

  7. Omega Therapeutics Inc (OMGA) Noticias

OMGA Omega Therapeutics Inc

2.145
-0.01 (-0.46%)
08 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Omega Therapeutics Inc OMGA NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.01 -0.46% 2.145 18:47:21
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.15 1.96 2.16 2.145 2.155
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
08/5/202406:00GLOBEOmega Therapeutics Presents New Preclinical Data at ASGCT..
06/5/202406:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/5/202406:04EDGAR2Form 8-K - Current report
06/5/202406:00GLOBEOmega Therapeutics Reports First Quarter 2024 Financial..
23/4/202406:00GLOBEOmega Therapeutics to Present New Preclinical Data on..
09/4/202406:00GLOBEOmega Therapeutics Presents New Preclinical Data at AACR..
28/3/202408:15GLOBEOmega Therapeutics Reports Fourth Quarter and Full Year 2023..
06/3/202406:00GLOBEOmega Therapeutics Announces Two Poster Presentations at the..
09/2/202416:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202416:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202415:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202415:00EDGAR2Form 8-K - Current report
02/1/202415:05GLOBEOmega Therapeutics to Present at the 42nd Annual J.P. Morgan..
11/12/202315:00EDGAR2Form 8-K - Current report
04/12/202315:00GLOBEOmega Therapeutics to Participate in the H.C. Wainwright 4th..
27/11/202318:01PRNUSFlagship Pioneering Marks Official Opening of UK Hub with..
21/11/202305:00PRNUSFlagship Pioneering Unveils Quotient Therapeutics to Create..
20/11/202315:00GLOBEOmega Therapeutics to Participate in the Piper Sandler 35th..
13/11/202306:00GLOBEOmega Therapeutics Showcases Bidirectional and Multiplexed..
09/11/202306:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202306:03EDGAR2Form 8-K - Current report
09/11/202306:00GLOBEOmega Therapeutics Reports Third Quarter 2023 Financial..
07/11/202315:00GLOBEOmega Therapeutics to Participate in The Jefferies London..
31/10/202306:00GLOBEOmega Therapeutics Presents New Preclinical Data..
16/10/202306:00GLOBEOmega Therapeutics Presents New Preclinical Data Supporting..
11/10/202315:00GLOBEOmega Therapeutics Announces Two Poster Presentations on..
04/10/202315:00GLOBEOmega Therapeutics to Present New Preclinical Data on..
26/9/202316:29EDGAR2Form 8-K - Current report
26/9/202306:00GLOBEOmega Therapeutics Announces Promising Preliminary Clinical..
25/9/202315:00GLOBEOmega Therapeutics to Host Conference Call to Discuss..
22/9/202316:10EDGAR2Form 8-K - Current report
21/9/202315:00GLOBEOmega Therapeutics to Participate in Two Upcoming Investor..
11/9/202305:30PRNUSFlagship Pioneering Announces Appointment of Amanda Kay as..
29/8/202315:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202315:30EDGAR2Form 3 - Initial statement of beneficial ownership of..
29/8/202306:03EDGAR2Form 8-K - Current report
29/8/202306:00GLOBEOmega Therapeutics Announces Updates to its Board of..
03/8/202316:13EDGAR2Form 8-K - Current report
03/8/202316:11EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
03/8/202315:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202315:00GLOBEOmega Therapeutics Reports Second Quarter 2023 Financial..
13/7/202315:00EDGAR2Form 8-K - Current report
12/7/202315:01EDGAR2Form 8-K - Current report
12/7/202306:00GLOBEOmega Therapeutics Appoints Chris Schade to its Board of..
01/6/202306:00GLOBEOmega Therapeutics to Participate in Two Upcoming Investor..
31/5/202307:30GLOBEAshvattha Therapeutics Expands Leadership Team with..
31/5/202306:00GLOBEOmega Therapeutics Presents New Preclinical Data..
16/5/202305:00PRNUSFlagship Pioneering Launches Metaphore Biotechnologies to..

Su Consulta Reciente

NASDAQ
OMGA
Omega Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados